IFNB1 and acute respiratory distress syndrome: A randomized controlled trial involving ARDS patients classified as moderate to severe according to the Berlin definition failed to demonstrate the efficacy of IFN-β administration [53], leading to recommendations against its routine use until new evidence is reported [54].